[Effect of Lactobacillus casei on the incidence of infectious conditions in children]
- PMID: 16913215
[Effect of Lactobacillus casei on the incidence of infectious conditions in children]
Abstract
Aim: To analyse the effect of continuous consumption of Lactobacillus casei (DN-114001) fermented milk on the incidence of the infectious disorders frequent in children. FIELD: Infant and child population
Subjects: children from 3 to 12 years from two schools in Barcelona. A total of 251 children from both sexes participated in the study.
Interventions: A nutritional intervention study was carried out during 20 weeks with a parallel, prospective, double-blind and randomised by pragmatic clusters design. Participants were children from 3 to 12 years from two schools in Barcelona. One of the centres was assigned to receive two daily units of Actimel" and the other to two units of Placebo. From the 251 participants, 109 receiving placebo and 142 receiving Actimel". Basal demographic characteristics and clinical history data were recorded, and the symptoms related to infectious disorders or other illnesses were monitored at weeks 12, 16 and 20. The analysis of the data was carried out on the intention-to-treat (ITT) population, being the principal endpoint the duration of respiratory and gastrointestinal symptoms.
Results: A one day difference, but non-significant, was seen in the median of total duration of days with illness through the study (Actimel group: 1 day vs Placebo group: 2 days). The same nonsignificant difference was also seen in the duration of days with respiratory (high and low respiratory tract infections) and with gastrointestinal (diarrhoea, vomiting, stomach pain and constipation) disorders. There was a statistical significantly difference found in favour of Actimel in the duration of the low respiratory tract infections, bronchitis or pneumonia, and in the duration of fatigue. There was also detected a lower incidence of children with low respiratory tract infections (32% vs. 49%) and with fatigue (3% vs. 13%) in the Actimel group compared to placebo. The satisfaction levels with the nutritional intervention were very high, over 80%.
Conclusions: The study shows a tendency to the reduction of duration and incidence of some infectious disorders in those children receiving two daily Actimel during 20 weeks.
Similar articles
-
Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial.Eur J Clin Nutr. 2010 Jul;64(7):669-77. doi: 10.1038/ejcn.2010.65. Epub 2010 May 19. Eur J Clin Nutr. 2010. PMID: 20485304 Free PMC article. Clinical Trial.
-
Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study.Am J Clin Nutr. 2015 Jun;101(6):1188-96. doi: 10.3945/ajcn.114.103531. Epub 2015 Apr 29. Am J Clin Nutr. 2015. PMID: 25926507 Clinical Trial.
-
Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study.J Nutr Health Aging. 2003;7(2):75-7. J Nutr Health Aging. 2003. PMID: 12679825 Clinical Trial.
-
Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial.J Am Coll Nutr. 2010 Oct;29(5):455-68. doi: 10.1080/07315724.2010.10719882. J Am Coll Nutr. 2010. PMID: 21504972 Clinical Trial.
-
Effects of a Fermented Dairy Drink Containing Lacticaseibacillus paracasei subsp. paracasei CNCM I-1518 (Lactobacillus casei CNCM I-1518) and the Standard Yogurt Cultures on the Incidence, Duration, and Severity of Common Infectious Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Nutrients. 2020 Nov 10;12(11):3443. doi: 10.3390/nu12113443. Nutrients. 2020. PMID: 33182682 Free PMC article.
Cited by
-
The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice.PLoS One. 2024 Oct 25;19(10):e0312318. doi: 10.1371/journal.pone.0312318. eCollection 2024. PLoS One. 2024. PMID: 39453930 Free PMC article.
-
Probiotics for preventing acute upper respiratory tract infections.Cochrane Database Syst Rev. 2022 Aug 24;8(8):CD006895. doi: 10.1002/14651858.CD006895.pub4. Cochrane Database Syst Rev. 2022. PMID: 36001877 Free PMC article.
-
Probiotics in respiratory virus infections.Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1289-302. doi: 10.1007/s10096-014-2086-y. Epub 2014 Mar 18. Eur J Clin Microbiol Infect Dis. 2014. PMID: 24638909 Free PMC article. Review.
-
Probiotics for preventing acute otitis media in children.Cochrane Database Syst Rev. 2019 Jun 18;6(6):CD012941. doi: 10.1002/14651858.CD012941.pub2. Cochrane Database Syst Rev. 2019. PMID: 31210358 Free PMC article.
-
The Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases.Front Immunol. 2022 May 31;13:908010. doi: 10.3389/fimmu.2022.908010. eCollection 2022. Front Immunol. 2022. PMID: 35711436 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources